Vidcast: https://youtu.be/V4K0AKnztjM
Here are the quickie reports about cutting edge medical and healthcare discoveries this 1st week of June, 2022.
A new Swiss perfusion technique keeps donor livers alive and well for up to 3 days while they await transplantation into recipients. In the past, the liver would only tolerate a 12 hour maximum residence outside the human body. The additional time allows transportation for longer distances as well as the laboratory and tissue testing necessary to assume a good match and long-term function.
https://www.nature.com/articles/s41587-022-01354-7
From NY’s Rockefeller University comes the news that a new synthetic antibiotic called cilagicin capably neutralizes even the nastiest, drug resistant bacteria including MRSA and C. difficile. The drug is based on a computer prediction regarding the type of molecule a bacterium would create to protect itself from its more aggressive cousins. Cilagicin works effectively by combining 2 molecules that together irreversibly weaken bacterial cells walls. Existing antibiotics have only one such molecule. The drug works in mice and is non-toxic to humans.
https://www.science.org/doi/10.1126/science.abn4213
A spoon full of sugar……. You know the rest. MIT bioengineers and Harvard gastroenterologists have a better way to make the medicines go down for those with difficulties swallowing, say after a stroke, or an aversion to pills and capsules as do most kids. Their better mousetrap is a gel-based drug delivery platform using gels composed of plant-based oils including sesame oil. The gels can be produced with different viscosities and flavors. Clinical studies are slated to begin soon.
https://www.science.org/doi/10.1126/sciadv.abm8478
The FDA has announced the first drug approved for the treatment of eosinophilic esophagitis. The drug is dupilumab and its better known as Dupixent. Its now approved for use in adults and teens 12 years and over weighing at least 88 pounds. Eosinophilic esophagitis is a chronic inflammation that triggers swallowing problems with food trapping on the way down to the stomach. Dupixent is about 60% effective in reducing the eosinophils populating the esophagus and driving this disorder. No word yet on insurance coverage.
https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-eosinophilic-esophagitis-chronic-immune-disorder
There you have the latest health reveals for the 1st week of June, 2022. When additional information about these developments becomes available, I’ll pass it on to you.
#liver #transplantation #perfusion #bacteria #antibiotic #drugresistant #ai #swallowing #gels #stroke #plantoil #esophagitis #eosinophil #dupi